$MYGN News

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

Myriad Genetics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6

Myriad Genetics, Inc. Q1 2026 Earnings Call Summary

Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $5.5

Myriad Genetics Q1 Earnings Call Highlights

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS

Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript

Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics Affirms FY2026 Sales Guidance of $860.000M-$880.000M vs $864.099M Est

Myriad Genetics Q1 Adj. EPS $(0.09) Misses $(0.07) Estimate, Sales $200.400M Miss $202.484M Estimate

Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan